Positive data from DREAMM-2 and DREAMM-6 trials of belantamab mafodotin in patients with relapsed/refractory multiple myeloma presented at conference
Thirteen month follow-up data from DREAMM-2 study of single-agent belantamab showed median duration of response of 11 months and overall survival of 14.9 months in heavily pre-treated patients who’d received median of 7 prior lines of treatment
Source:
Biospace Inc.
SPS commentary:
Preliminary analysis of DREAMM-6 study examining belantamab mafodotin in combination with bortezomib/dexamethasone in patients whose disease has become refractory or relapsed after one or more prior lines of treatment reported overall response rate of 78% (14 of 18 patients).
In Feb 2020, the European Medicines Agency accepted a marketing authorisation application for this investigational anti-BCMA (antibody drug conjugate against B-cell maturation antigen) agent for the treatment of relapsed or refractory multiple myeloma.